Bayer-Vitiva partnership
This article was originally published in The Tan Sheet
Executive Summary
Bayer Pharmaceuticals and Vitiva have signed an agreement to develop exclusive isolation of esters from marigold flowers, the firms announce July 5. The initiatve is related to Bayer's registered patent for a natural OTC product based on marigold flower extract, a press release adds. The partnership will "stimulate development of innovative products and will deliver new solutions for consumers who prefer to use natural ingredients," Vitiva says. Bayer Pharmaceuticals is part of the new Global Pharmaceutical Division that was established Jan. 1 and grew out of the former Biological Products and Pharmaceutical Division...
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.